WO2001030392A3 - Delivery of proteins across polar epithelial cell layers - Google Patents

Delivery of proteins across polar epithelial cell layers Download PDF

Info

Publication number
WO2001030392A3
WO2001030392A3 PCT/US2000/029080 US0029080W WO0130392A3 WO 2001030392 A3 WO2001030392 A3 WO 2001030392A3 US 0029080 W US0029080 W US 0029080W WO 0130392 A3 WO0130392 A3 WO 0130392A3
Authority
WO
WIPO (PCT)
Prior art keywords
bioactive
proteins
delivery
epithelial cell
cell layers
Prior art date
Application number
PCT/US2000/029080
Other languages
French (fr)
Other versions
WO2001030392A2 (en
Inventor
David J Fitzgerald
Randall J Mrsny
Miriam Mckee
Ann Daugherty
Original Assignee
Us Gov Health & Human Serv
Genentech Inc
David J Fitzgerald
Randall J Mrsny
Miriam Mckee
Ann Daugherty
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Genentech Inc, David J Fitzgerald, Randall J Mrsny, Miriam Mckee, Ann Daugherty filed Critical Us Gov Health & Human Serv
Priority to CA2389302A priority Critical patent/CA2389302C/en
Priority to JP2001532809A priority patent/JP2003512441A/en
Priority to AU13392/01A priority patent/AU784657B2/en
Priority to AT00975326T priority patent/ATE444081T1/en
Priority to US10/110,880 priority patent/US7824695B1/en
Priority to EP00975326A priority patent/EP1242122B1/en
Priority to DE60043070T priority patent/DE60043070D1/en
Publication of WO2001030392A2 publication Critical patent/WO2001030392A2/en
Publication of WO2001030392A3 publication Critical patent/WO2001030392A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

This invention provides bioactive conjugates. The bioactive conjugates include: (1) a cell recognition moiety that binds to α2 macroglobulin receptor α2-MR and (2) a bioactive moiety which: (a) has a biological activity, (b) does not function solely as an immunogen to invoke an immune response and (c) does not have ADP ribosylating activity. The bioactive conjugates of this invention are useful in methods of transporting the bioactive moiety across a polar epithelial membrane. Thus, this invention provides methods for parenteral administration of proteins without injection.
PCT/US2000/029080 1999-10-22 2000-10-18 Delivery of proteins across polar epithelial cell layers WO2001030392A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2389302A CA2389302C (en) 1999-10-22 2000-10-18 Delivery of proteins across polar epithelial cell layers
JP2001532809A JP2003512441A (en) 1999-10-22 2000-10-18 Delivery of proteins across polar epithelial cell layers
AU13392/01A AU784657B2 (en) 1999-10-22 2000-10-18 Delivery of proteins across polar epithelial cell layers
AT00975326T ATE444081T1 (en) 1999-10-22 2000-10-18 PROTEINS RELEASE THROUGH POLAR EPITHELIAL CELL LAYER
US10/110,880 US7824695B1 (en) 1999-10-22 2000-10-18 Delivery of proteins across polar epithelial cell layers
EP00975326A EP1242122B1 (en) 1999-10-22 2000-10-18 Delivery of proteins across polar epithelial cell layers
DE60043070T DE60043070D1 (en) 1999-10-22 2000-10-18 PROTEIN DELIVERY BY POLAR EPITHELIAL CELLS LAYER

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16092399P 1999-10-22 1999-10-22
US60/160,923 1999-10-22

Publications (2)

Publication Number Publication Date
WO2001030392A2 WO2001030392A2 (en) 2001-05-03
WO2001030392A3 true WO2001030392A3 (en) 2002-07-11

Family

ID=22579051

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/029080 WO2001030392A2 (en) 1999-10-22 2000-10-18 Delivery of proteins across polar epithelial cell layers

Country Status (8)

Country Link
US (1) US7824695B1 (en)
EP (1) EP1242122B1 (en)
JP (2) JP2003512441A (en)
AT (1) ATE444081T1 (en)
AU (1) AU784657B2 (en)
CA (1) CA2389302C (en)
DE (1) DE60043070D1 (en)
WO (1) WO2001030392A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510683A (en) * 1997-07-11 2001-08-07 ザ ガバメント オブ ザ ユナイテッド ステイツ リプリゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Pseudomonas exotoxin A-like chimeric immunogen
DE60043070D1 (en) * 1999-10-22 2009-11-12 Genentech Inc PROTEIN DELIVERY BY POLAR EPITHELIAL CELLS LAYER
CA2583202A1 (en) * 2004-10-04 2006-04-27 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
CA2631981A1 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
WO2007067596A2 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of antibodies
EP2010205A2 (en) * 2006-03-16 2009-01-07 Trinity Biosystems, Inc. Methods for increasing the size of animals using needleless delivery constructs
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
SG11202009925PA (en) 2018-03-08 2020-11-27 Applied Molecular Transport Inc Toxin-derived delivery constructs for oral delivery
IL282986B2 (en) 2018-11-07 2024-01-01 Applied Molecular Transport Inc Cholix-derived carriers for oral delivery of heterologous payload
CA3150859A1 (en) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations, and interleukin production and purification

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986006635A1 (en) * 1985-05-15 1986-11-20 Biotechnology Australia Pty. Ltd. Oral vaccines
WO1995007297A1 (en) * 1993-09-06 1995-03-16 Menarini Ricerche Sud S.P.A. Ribosome inactivating proteins extracted from seeds of saponaria ocymoides and vaccaria pyramidata, their preparation and immunotoxins containing them
WO1998042876A1 (en) * 1997-03-26 1998-10-01 Board Of Regents, The University Of Texas System Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
WO2000046246A1 (en) * 1999-02-02 2000-08-10 The General Hospital Corporation Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease
WO2001030392A2 (en) * 1999-10-22 2001-05-03 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Delivery of proteins across polar epithelial cell layers
WO2001031020A1 (en) * 1999-10-22 2001-05-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Disulfide conjugated cell toxins and methods of making and using them

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2138020C (en) * 1992-06-23 1999-02-16 Eric A. Johnson Pharmaceutical composition containing botulinum b complex
ATE204300T1 (en) 1994-05-13 2001-09-15 Biovation Ltd TARGET CELL-BINDING CHIMERIC PEPTIDES
US6426075B1 (en) * 1996-11-06 2002-07-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Protease-activatable pseudomonas exotoxin A-like proproteins
JP2001510683A (en) * 1997-07-11 2001-08-07 ザ ガバメント オブ ザ ユナイテッド ステイツ リプリゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Pseudomonas exotoxin A-like chimeric immunogen
US20030054012A1 (en) 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
DE60137969D1 (en) 2000-12-21 2009-04-23 Us Gov Health & Human Serv A CHIMERIC PROTEIN CONTAINING NONTOXIC PSEUDOMONAS EXOTOXIN A AND TYPE IV PILIN SEQUENCES

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986006635A1 (en) * 1985-05-15 1986-11-20 Biotechnology Australia Pty. Ltd. Oral vaccines
WO1995007297A1 (en) * 1993-09-06 1995-03-16 Menarini Ricerche Sud S.P.A. Ribosome inactivating proteins extracted from seeds of saponaria ocymoides and vaccaria pyramidata, their preparation and immunotoxins containing them
WO1998042876A1 (en) * 1997-03-26 1998-10-01 Board Of Regents, The University Of Texas System Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
WO2000046246A1 (en) * 1999-02-02 2000-08-10 The General Hospital Corporation Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease
WO2001030392A2 (en) * 1999-10-22 2001-05-03 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Delivery of proteins across polar epithelial cell layers
WO2001031020A1 (en) * 1999-10-22 2001-05-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Disulfide conjugated cell toxins and methods of making and using them

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANDREASEN P.A. ET AL: "Receptor -mediated endocytosis of plasminogen activators and activator/inhibitor complexes.", FEBS LETTERS, (1994) 338/3 (239-245)., XP002184228 *
CAVALLARO, UGO ET AL: "Targeting plant toxins to the urokinase and.alpha.2- macroglobulin receptors", SEMIN. CANCER BIOL. (1995), 6(5), 269-78, XP001041657 *
DAUGHERTY, A. L. ET AL: "Epithelial application of Pseudomonas aeruginosa exotoxin A results in a selective targeting to cells in the liver, spleen and lymph node", J. CONTROLLED RELEASE (2000), 65(1-2), 297-302, XP002184229 *
MAZIERE, J. C. ET AL: "Processing and characterization of the low density lipoprotein receptor i the human colonic carcinoma cell subclone HT29-18: a potential pathway fo delivering therapeutic drugs and genes", BIOSCI. REP. (1992), 12(6), 483-94, XP001041571 *
ZDANOVSKY, ALEXEY G. (1) ET AL: "Targeting of pseudomonas and diphtheria toxins to the alpha-2- macroglobulin receptor via RAP-toxin and PAI-I-toxin fusions.", PROTEIN ENGINEERING, (1995) VOL. 8, NO. SUPPL., PP. 123. MEETING INFO.: MIAMI BIO/TECHNOLOGY WINTER SYMPOSIUM ON ADVANCES IN GENE TECHNOLOGY: PROTEIN ENGINEERING AND STRUCTURAL BIOLOGY MIAMI, FLORIDA, US FEBRUARY 4-9, 1995, XP001041495 *

Also Published As

Publication number Publication date
CA2389302C (en) 2011-03-15
WO2001030392A2 (en) 2001-05-03
AU1339201A (en) 2001-05-08
AU784657B2 (en) 2006-05-18
DE60043070D1 (en) 2009-11-12
JP2012051939A (en) 2012-03-15
EP1242122A2 (en) 2002-09-25
EP1242122B1 (en) 2009-09-30
CA2389302A1 (en) 2001-05-03
JP2003512441A (en) 2003-04-02
ATE444081T1 (en) 2009-10-15
US7824695B1 (en) 2010-11-02

Similar Documents

Publication Publication Date Title
WO2005055950A3 (en) Glycopegylated factor ix
DK1323346T3 (en) Receptor-specific transport of immunogens through the epithelium
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
PT817847E (en) IL-17 RECEPTOR
NO891711D0 (en) HIV ENV-CODED PEPTIDE AFFECTED FOR AA INJECTION ANTI-INHIBITIVE ANTIBODIES IN MAMMALS.
EP0510949A3 (en) Cytomodulating conjugates of members of specific binding pairs
BR0314092A (en) modified transferrin fusion proteins
EP2272859A3 (en) Immunological herpes simplex virus antigens and methods for use thereof
WO2005051327A3 (en) Glycopegylated erythropoietin
WO2001030392A3 (en) Delivery of proteins across polar epithelial cell layers
WO2006031811A3 (en) Glycopegylated interferon alpha
BR0314093A (en) Modified transferrin-antibody fusion proteins
DE570357T1 (en) Peptides that induce antibodies that neutralize genetically divergent HIV-1 isolations.
DE69830492D1 (en) Antibodies as medicines against lymphocytic tumors (excluding myeloma)
EP0866133A3 (en) A group b streptococcus vaccine
ATE328611T1 (en) MULTIPLE CARBOHYDRATE-CONTAINING GLYCOPEPTIDE ANTIGENS, VACCINES DEVELOPED THEREFROM AND THEIR USE
DE69726674T2 (en) CELL-MODULATING CONJUGATES FROM ELEMENTS FROM SPECIFIC BINDING PAIRS
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
WO2004062588A3 (en) Water-soluble polymeric bone-targeting drug delivery system
WO1993019178A3 (en) Peptides useful for inducing tolerance
EP1354896A4 (en) Novel monoclonal antibody
DE69841260D1 (en) BACTERIAL PHEROMONE AND ITS USES
NL1002202C2 (en) Chair, especially chair for students.
WO2000064928A3 (en) Transmembrane (7tm) receptor r35)
WO2000061747A3 (en) Clasp-2 transmembrane proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10110880

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2389302

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 532809

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 13392/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000975326

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000975326

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)